CD274 and non-small cell lung carcinoma: Many kinds of programmed death-1 (PD-1) and its ligand (PD-L1) monoclonal antibodies have been approved and applied to the treatment of advanced or locally advanced NSCLC (10), opening up a new horizon in NSCLC treatment.